STGD1
Clinical trials for STGD1 explained in plain language.
Never miss a new study
Get alerted when new STGD1 trials appear
Sign up with your email to follow new studies for STGD1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to slow vision loss in rare genetic eye disease
Disease control Recruiting nowThis clinical trial is testing whether a medication called tinlarebant can slow the progression of Stargardt disease, a genetic condition that causes vision loss. The study involves 60 participants who will take either the drug or a placebo daily for two years while researchers m…
Matched conditions: STGD1
Phase: PHASE2, PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Feb 23, 2026 14:53 UTC
-
Scientists map vision loss to pave way for future cures
Knowledge-focused Recruiting nowThis study aims to better understand how Stargardt disease, a genetic eye condition that causes vision loss, progresses over time. Researchers will follow about 75 people with the disease, using eye scans and vision tests to track changes. The information gathered will help scien…
Matched conditions: STGD1
Sponsor: Splice Bio • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC